Joint Clinical Assessment, JCA
Mezigdomide (multiple myeloma)
Dossier assessment
Indication:
Treatment of multiple myeloma
Timetable
- 2nd quarter, 2026
- Start
- 3rd quarter, 2027
- voraussichtlicher Abschluss
Project details
- Project no.
- MP-202544
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission work started
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the Agency for Health Technology Assessment and Tariff System (AOTMiT) Poland.
Further background information can be found here: European health technology assessment